#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating children with drug-resistant epilepsy need to understand that despite legal changes enabling medical cannabis prescribing in the UK, NHS access remains severely restricted, forcing families toward private prescribers or illicit sources. This access gap represents a critical clinical care disparity where evidence-based treatment options exist but remain unavailable to vulnerable pediatric patients, requiring clinicians to advocate for policy changes or navigate complex referral pathways. Patients and families should know that ongoing campaigns may improve NHS coverage, potentially making this treatment option more accessible and affordable for eligible children who have exhausted conventional anticonvulsant therapies.
A grassroots campaign has been launched to increase NHS access to medical cannabis for children with drug-resistant epilepsy, inspired by a mother whose advocacy contributed to the 2018 legalization of cannabis-based medicinal products in the United Kingdom. Despite the legal framework allowing medical cannabis prescriptions, significant barriers remain in clinical practice, with NHS funding and formulary restrictions preventing most eligible pediatric patients from obtaining these treatments even when conventional antiepileptic drugs have failed. The campaign highlights a critical gap between policy and implementation, where children who could potentially benefit from cannabidiol or whole-plant cannabis products remain unable to access them through standard NHS pathways due to cost, prescribing limitations, and lack of specialist infrastructure. This advocacy effort underscores the persistence of regulatory and financial obstacles that have characterized medical cannabis access in the UK since legalization, despite growing evidence supporting its efficacy in specific pediatric seizure disorders like Dravet syndrome and Lennox-Gastaut syndrome. Clinicians caring for children with refractory epilepsy should be aware of the ongoing access barriers to NHS-funded cannabis-based treatments and may need to explore private prescription routes or clinical trial options for eligible patients when conventional therapies prove insufficient. Patients and families should engage with advocacy campaigns and their local representatives to push for expanded NHS coverage, as current restrictions may prevent access to potentially life-changing treatment options.
“What we’re seeing with these families is the tragic gap between what the evidence supports and what the system allows, and it falls hardest on children who have already exhausted conventional options and have nothing left to lose. The NHS needs to establish clear pathways for cannabis-based treatments in drug-resistant epilepsy rather than forcing families into the impossible choice between breaking the law or watching their children seize uncontrolled.”
💊 While medical cannabis has shown promise for severe, drug-resistant epilepsy in controlled trials, significant gaps remain between regulatory approval and clinical accessibility in the UK. The current barriers to NHS prescribing of cannabis-based products reflect legitimate concerns about evidence quality, standardization, manufacturing consistency, and long-term safety data in pediatric populations, though these constraints also limit access for children who have exhausted conventional options and may genuinely benefit. Clinicians caring for families with intractable epilepsy should recognize the tension between the cautious regulatory approach and the real clinical desperation of families seeking alternatives, while remaining aware that outcome data from recent trials like GWPCARE1 do support efficacy in specific cannabinoid formulations. Rather than viewing this as a simple access issue, practitioners should engage in shared decision-making conversations that honestly acknowledge both the evidence supporting certain cannabis-derived products for refractory seizures and the legitimate unknowns regarding dose
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: